KTTA

Pasithea Therapeutics Corp.

Pharmaceutical Preparations · SIC 2834CIK 1841330Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(20.0M)

EPS (Basic, as reported)

$-2.91

Net Margin FY2025

—

ROE FY2025

-37.0%

Total Equity

$55.0M

Shares Out

33M

Business description

Pasithea Therapeutics Corp. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 0

Fiscal yearFY2020FY2021⚑FY2022⚑FY2023FY2024⚑FY2025

Revenue—00———

Cost of revenue—00———

Gross profit—0————

Research & development——(3)(8)(7)(8)

Selling, general & administrative—(5)(13)(8)(7)—

General & administrative————(7)(13)

Total operating expenses——(1)———

Operating income—(5)(15)(16)(14)(21)

Interest expense—00———

Interest & investment income———000

Other income (expense), net—21000

Pre-tax income—(2)(14)(16)(14)(20)

Net income—(2)(14)(16)(14)(20)

EPS — basic—($0.21)($0.55)($0.42)($12.69)($2.91)

EPS — diluted—($0.21)($0.53)($0.42)($12.69)($2.91)

Shares outstanding — basic (M)—1025117

Shares outstanding — diluted (M)—1025117

⚑ Weighted-average shares changed ×2.50 between FY2021 and FY2022 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ÷25.00 between FY2022 and FY2023 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×7.00 between FY2024 and FY2025 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.